Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Goldman Sachs Downgrades Frequency Therapeutics to Neutral, Lowers Price Target to $9

Goldman Sachs analyst Paul Choi downgrades Frequency Therapeutics (NASDAQ:FREQ) from Buy to Neutral and lowers the price target from $12 to $9.
byvishwanath@benzinga.com
September 22, 2021
1 minute read
Total
0
Shares
0
0
0
0
0
0

Goldman Sachs analyst Paul Choi downgrades Frequency Therapeutics (NASDAQ:FREQ) from Buy to Neutral and lowers the price target from $12 to $9.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0